Peptic Ulcer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Proton Pump Inhibitors, Potassium-Competitive Acid Blocker (P-CAB), Antacids, H2- Antagonist, Antibiotics, Ulcer Protective), By Disease Indication (Gastitis, Gastric Ulcer, Duodenal Ulcer, Gastroesophageal Reflux Disease (GERD)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce), By Region and Competition, 2020-2030F

Market Overview

The Global Peptic Ulcer Drugs Market will grow from USD 3.54 Billion in 2024 to USD 4.31 Billion by 2030 at a 3.32% CAGR. Peptic ulcer drugs comprise pharmaceutical agents formulated to treat open sores that develop on the lining of the stomach, small intestine, or esophagus, primarily resulting from *Helicobacter pylori* infection or prolonged use of nonsteroidal anti-inflammatory drugs. The market's expansion is fundamentally driven by the escalating global prevalence of *H. pylori* infections and the extensive use of NSAIDs. Furthermore, lifestyle-related factors, including unhealthy diets, increased stress levels, and rising obesity rates, significantly contribute to the incidence of peptic ulcers. According to the Centers for Disease Control and Prevention, in September 2024, the prevalence of obesity among adults was 40.3% between August 2021 and August 2023, influencing the demand for related treatments.

A significant impediment to sustained market growth is the increasing antibiotic resistance observed in *H. pylori* eradication regimens. This challenge reduces the effectiveness of current first-line therapies, potentially leading to treatment failures and extended recovery periods for patients.

Key Market Drivers

The global peptic ulcer drugs market is significantly driven by the persistent high incidence of *Helicobacter pylori* infection. This bacterium is a primary etiological factor for peptic ulcer disease, necessitating targeted antimicrobial and acid-suppressing therapies for successful eradication and healing. The widespread nature of this infection ensures a continuous and substantial patient pool requiring diagnostic procedures and a comprehensive array of pharmaceutical interventions. According to "Gastroenterology", in April 2024, in the article "Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022", the crude global prevalence of *H. pylori* in adults was 43.9% during 2015 through 2022, underscoring the enduring demand for effective treatments.

Concurrently, the widespread use of non-steroidal anti-inflammatory drugs, or NSAIDs, represents another critical driver for the peptic ulcer drugs market. These medications, widely prescribed for pain and inflammation, are well-known to cause gastrointestinal mucosal damage, leading to ulcer formation and serious complications such as bleeding. The sustained and extensive application of NSAIDs across various therapeutic areas contributes to a significant cohort of individuals susceptible to these adverse events. According to "Korean Journal of Helicobacter and Upper Gastrointestinal Research", in March 2025, in the article "Nonsteroidal Anti-Inflammatory Drug-Induced Peptic Ulcer Disease", studies report a global prevalence rate of gastric ulcers for 10% of NSAID users, highlighting the substantial contribution of these drugs to peptic ulcer pathology. The interplay between these major risk factors further escalates the market's trajectory; according to "The Korean Journal of Helicobacter and Upper Gastrointestinal Research", in February 2025, in the article "Nonsteroidal Anti-Inflammatory Drug-Induced Peptic Ulcer Disease", a meta-analysis showed that patients with both *H. pylori* infection and NSAID use have a 3.53-fold higher risk of peptic ulcers and complications, illustrating the compounded demand for advanced treatment options.

Download Free Sample Report

Key Market Challenges

A significant impediment to the sustained expansion of the global peptic ulcer drugs market is the escalating antibiotic resistance encountered in *Helicobacter pylori* eradication regimens. This challenge directly undermines the effectiveness of established first-line therapies, leading to suboptimal patient outcomes. When bacteria develop resistance to antibiotics, the standard treatment protocols become less efficacious, often necessitating longer treatment durations, the use of more complex drug combinations, or the administration of higher doses, all of which increase treatment burden and healthcare costs.

The rising resistance rates contribute to treatment failures and extended recovery periods for individuals suffering from peptic ulcers. According to the American College of Gastroenterology, in their 2024 clinical guideline, *H. pylori* resistance rates in the United States were reported at 32% for clarithromycin, 38% for levofloxacin, and 42% for metronidazole, all of which are critical antibiotics in current treatment regimens. This widespread resistance diminishes the overall success rates of existing pharmaceutical interventions, thereby dampening demand for drugs that are increasingly perceived as ineffective. Consequently, this factor directly hampers market growth by reducing the reliability of current drug portfolios and increasing the need for costly, less accessible alternative therapies.

Key Market Trends

The global peptic ulcer drugs market is experiencing a significant shift towards Potassium-Competitive Acid Blockers (P-CABs), marking an advancement in acid suppression therapy. P-CABs offer benefits such as rapid onset and consistent acid suppression, addressing limitations of traditional proton pump inhibitors. Their integration into treatment protocols is expanding, especially for patients unresponsive to conventional therapies. According to the American Gastroenterological Association's Clinical Practice Update, published in January 2025, P-CABs are recommended in place of proton pump inhibitors for most patients with *Helicobacter pylori* and other conditions where initial therapies have failed. This expanded role reflects increasing confidence in P-CAB efficacy within clinical practice.

A critical trend in the peptic ulcer drugs market is the heightened focus on developing and implementing novel *Helicobacter pylori* eradication regimens, driven by escalating antibiotic resistance. The diminishing efficacy of conventional antibiotic combinations necessitates new therapeutic strategies. The American College of Gastroenterology's 2024 clinical guideline on *Helicobacter pylori* infection treatment, published in September 2024, recommends optimized bismuth quadruple therapy for 14 days as the preferred regimen for treatment-naïve patients when antibiotic susceptibility is unknown. This shift is vital as resistance rates continue to climb; an international survey cited in "Helicobacter pylori antibiotic resistance: a global challenge in search of solutions," published in Gut in September 2025, reported that clarithromycin and levofloxacin resistance exceeds 15% in 24 of 31 and 18 of 31 surveyed countries, respectively. This necessitates continuous innovation in treatment protocols.

Segmental Insights

Within the global peptic ulcer drugs market, Proton Pump Inhibitors (PPIs) represent the fastest-growing segment, primarily driven by their superior efficacy and favorable safety profile. These medications effectively reduce stomach acid production, leading to high ulcer healing rates and sustained symptom relief, establishing them as a preferred first-line treatment option for peptic ulcers. The segment's rapid expansion is further supported by the increasing global prevalence of gastrointestinal disorders, including peptic ulcers and gastroesophageal reflux disease, alongside advancements in drug formulations that enhance bioavailability and patient compliance. Physician preference for PPIs due to their proven effectiveness also contributes significantly to this growth.

Regional Insights

North America leads the global peptic ulcer drugs market, driven by its advanced healthcare infrastructure and high prevalence of peptic ulcer disease due to factors such as *H. pylori* infections and widespread nonsteroidal anti-inflammatory drug use. The region benefits from substantial investments in pharmaceutical research and development, fostering innovative drug formulations and advanced treatment options. Furthermore, high patient awareness and early diagnosis contribute significantly to market expansion. The robust regulatory framework provided by agencies like the U.S. Food and Drug Administration also ensures stringent quality standards and facilitates the availability of effective therapies.

Recent Developments

• In May 2025, results from a Phase III, randomized, double-blind, multicenter trial evaluating keverprazan for the treatment of duodenal ulcers were published. The study, conducted in Chinese patients, demonstrated that keverprazan 20 mg was non-inferior to lansoprazole 30 mg in achieving duodenal ulcer healing at both six and four weeks. This breakthrough research highlights keverprazan as a promising novel potassium-competitive acid blocker with a favorable safety profile, poised to offer an effective alternative for patients with acid-related disorders.

• In July 2024, Phathom Pharmaceuticals received U.S. Food and Drug Administration (FDA) approval for VOQUEZNA (vonoprazan) 10 mg tablets. This approval is specifically for the daily treatment of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) in adults. Vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), represents a significant advancement in acid suppression therapy, offering patients a novel treatment option to effectively reduce heartburn symptoms for the largest category of GERD.

• In July 2024, Mankind Pharma also entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company for the commercialization of Vonoprazan in the Indian market. This strategic collaboration allows Mankind Pharma to introduce Takeda’s potassium-competitive acid blocker, "Vault" (Vonoprazan), under its own trademark. The deal aims to further broaden the availability of this important gastrointestinal drug for treating Gastroesophageal Reflux Disease and other acid-related disorders across India.

• In June 2024, Sun Pharmaceutical Industries announced a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company to commercialize Vonoprazan tablets in India under the brand name "Voltapraz." This collaboration brings Takeda's novel potassium-competitive acid blocker, designed to treat reflux esophagitis and other acid peptic disorders, to the Indian market. The agreement leverages Sun Pharma’s leadership in gastroenterology, providing a new treatment option for managing these conditions and expanding access to advanced therapies in the region.

Key Market Players

• Daewoong Pharmaceutical Co., Ltd
• Takeda Pharmaceutical Co., Ltd.
• Pfizer Inc.
• AstraZeneca plc.
• RedHill Biopharma Ltd.
• Zydus Lifesciences Limited
• ANI Pharmaceuticals, Inc. (Novitium Pharma LLC.)
• Boehringer Ingelheim International GmbH
• Eisai Co. Ltd.
• Yuhan Corporation

Report Scope:

In this report, the Global Peptic Ulcer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Peptic Ulcer Drugs Market, By Product Type:

o   Proton Pump Inhibitors

o   Potassium-Competitive Acid Blocker (P-CAB)

o   Antacids

o   H2- Antagonist

o   Antibiotics

o   Ulcer Protective

• Peptic Ulcer Drugs Market, By Disease Indication:

o   Gastitis

o   Gastric Ulcer

o   Duodenal Ulcer

o   Gastroesophageal Reflux Disease (GERD)

• Peptic Ulcer Drugs Market, By Distribution Channel:

o   Hospital Pharmacies

o   Retail Pharmacies

o   E-Commerce

• Peptic Ulcer Drugs Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Peptic Ulcer Drugs Market.

Available Customizations:

Global Peptic Ulcer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Peptic Ulcer Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]